Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HY-088 is an ultrasmall superparamagnetic iron oxide nanoparticle (USPIO) injection being developed as a contrast agent for magnetic resonance imaging (MRI). The drug consists of iron oxide crystals coated with polyacrylic acid (PAA) on the surface, which serves to stabilize the nanoparticles and enhance their biocompatibility. Developed by Sichuan Huiyu Seacross Pharmaceutical (a subsidiary of Huiyu Pharmaceutical) in collaboration with InnoStar Bio-tech, HY-088 functions by shortening the T2 and T2* relaxation times of water protons in the surrounding tissue, thereby improving image contrast. Preclinical studies in rat models have characterized its pharmacokinetic profile and tissue distribution, supporting its potential use in diagnostic imaging applications.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on HY-088.